Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...

Analyst Joseph Schwartz from Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report) and increased the price ...

President-elect Donald Trump hosted the chief executives of Pfizer, Eli Lilly and PhRMA at Mar-a-Lago for a dinner with ...

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

A roundup of significant health updates globally includes Sanofi's major investment in China, New Zealand suspending poultry ...

RBC Capital has upgraded PTC Therapeutics (PTCT) to outperform from sector perform on the company’s deal with Novartis (NVS) ...